We also observed associations with NSCLC risk of some polymorphisms of non-classical HLA-I gene, HLA-G, and of LILRB1 encoding an inhibitory cell surface receptor expressed by lymphoid and myeloid cells, which binds a broad range of HLA-I molecules, but preferentially interacts with HLA-G (95). This evidence concerns the gene HLA-G and non-small cell lung carcinoma.